Bicara Therapeutics
BCAX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -3.4% in FY2025
Claire Mazumdar, Ph.D. is the CEO of Bicara Therapeutics and was paid $927.7K in FY2025 (Dec), down 90%.
Pay$100 in the stock at the end of FY24 → $97
Executives3
See all- 1Claire Mazumdar, Ph.D.Chief Executive OfficerFY2025
- 2Ryan Cohlhepp, Pharm.D.President and Chief Operating OfficerFY2025
- 3David Raben, M.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allBicara Therapeutics paid its 3 named executives $2.5M in total in FY2025 (Dec). CEO Claire Mazumdar, Ph.D. was paid $927.7K of that.
| Name | |||
|---|---|---|---|
| Claire Mazumdar, Ph.D.Chief Executive Officer | |||
| Ryan Cohlhepp, Pharm.D.President and Chief Operating Officer | Not disclosed | ||
| David Raben, M.D.Chief Medical Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Bicara Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Kiran Mazumdar-ShawDirector · 7 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Scott RobertsonDirector · 2 yr on the boardIndependentAudit (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings4
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Mar 30, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 27, 2025 | FY2024 |
